CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 90 enrolled
Drug / intervention
Fish oil (eicosapentaenoic acid and docosahexanoic acid)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00351533
NCT00351533Phase 2Completed
CompareCT.gov

A Randomized, Double-blind Study of the Effect of Fish Oil (Eicosapentaenoic Acid and Docosahexanoic Acid) on Lung and Systemic Inflammation in Patients With Acute Lung Injury (ALI)

University of Washington·interventional·Posted Jul 13, 2006·Updated Oct 3, 2011

In Brief

A Phase 2 clinical trial evaluating Fish oil (eicosapentaenoic acid and docosahexanoic acid) for Respiratory Distress Syndrome, Adult and 2 related conditions. Completed, enrolled 90 participants across 5 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine whether fish oil (containing omega-3 fatty acids) given enterally is safe and effective in reducing lung and systemic inflammation seen in acute lung injury.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
CountriesCanada, United States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), American Thoracic Society, Acute Respiratory Distress Syndrome Foundation, American Society for Parenteral and Enteral Nutrition

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 13, 2006
Enrollment StartJul 1, 2006
Primary CompletionJan 1, 2009
Study CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 20.0 years ago

Interventions

Fish oil (eicosapentaenoic acid and docosahexanoic acid)drug

Liquid fish oil 7.5cc enterally every 6 hours